Menghis Bairu, M.D.
Founder, Chairman, and CEO
Menghis Bairu, M.D. is a physician, business executive, editor, author, and philanthropist. He has more than 25 years of international experience in the biotechnology, pharmaceutical, drug delivery and device, global health, and non-profit arenas.
Dr. Bairu is Executive Chairman of Treos Bio, a start-up company that uses computational biology to develop precision cancer immunotherapies tailored to patients' genetics. In addition, he is Founder and Chairman Emeritus of Serenus Biotherapeutics, an emerging markets focused specialty biopharmaceutical company. In that role he raised up to $43 million in series A funding.
Prior to that, Dr. Bairu concurrently served as Executive Vice President, Chief Medical Officer, Head of Global Development for Elan and President/CEO of Speranza Therapeutics, Elan’s wholly owned subsidiary formed to develop new therapies for multiple indications. As EVP and CMO, Dr. Bairu was member of the Elan’s Operating Committee. He successfully led corporate R&D due diligence processes that resulted in a transaction with J&J at a value of approximately $1.5 billion. In 2013, he also led corporate R&D due diligence resulting in the sale of Elan to Perrigo for $8.6 billion. The combined company incorporated in Ireland as Perrigo plc with a marketing capitalization of approximately $20 billion.
Prior to joining Elan, Dr. Bairu worked at Genentech for more than six years in a number of managed care, medical, and commercial roles (Rituximab, Herceptin, TNK, tPA, Growth Hormone: current aggregate sale over $10 billion per year). He also served on the board of directors of various companies, including One World Health, a non-profit drug development company funded by the Bill and Melinda Gates Foundation; A-Cube, a privately held biotechnology start-up company; and a member of the board of directors of Dubai-based NewBridge Pharmaceuticals.
Dr. Bairu currently serves as Adjunct Professor at the University of California, San Francisco School of Medicine where he lectures on global clinical trials’ design, development, and conduct.